COMMUNIQUÉS West-GlobeNewswire

Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer
01/05/2024
Industry veteran Douglas Carlson to steer Avalyn’s finance and business functions as company nears late-stage clinical development for lead programs CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc [...]
AltruBio to Participate in Upcoming May 2024 Medical Conferences
01/05/2024
SAN FRANCISCO, May 01, 2024 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological [...]
Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
01/05/2024
Additional data from the Phase 2 ARCHER trial demonstrating protection of visual acuity and anatomical structure following ANX007 treatment will be featured as an oral presentation New preclinical data on the pathogenic [...]
BetterLife Advances BETR-001 IND-enabling Studies
01/05/2024
VANCOUVER, British Columbia, May 01, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and [...]
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
01/05/2024
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain [...]
ImmuneSensor Therapeutics Appoints Veteran Biopharma Executive, Thomas W. Dubensky, Jr., Ph.D., as Chief Executive Officer
01/05/2024
Company debuts with pipeline of cGAS-STING pathway inhibitors and agonists DALLAS, May 01, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of best- [...]
Bionano to Report First Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 8, 2024
01/05/2024
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to report [...]
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference
01/05/2024
HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines [...]
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
01/05/2024
NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will [...]
Inovalon Earns 2024 Great Place To Work® Certification™ For Second Consecutive Year
01/05/2024
Sustained Recognition Reflects Longstanding Commitment to Enhanced Employee Experiences and Well-being BOWIE, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Inovalon , a leading provider of cloud-based software solutions [...]
4DMT Announces Presentations at ARVO 2024 Annual Meeting
01/05/2024
Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation 4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a poster EMERYVILLE, [...]
Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
01/05/2024
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
01/05/2024
Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease Akari Therapeutics announces leadership changes in separate Akari [...]
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
01/05/2024
CORAL GABLES, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and [...]
Aeterna Zentaris Announces Effective Date of Share Consolidation
01/05/2024
TORONTO, ON, May 01, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ” or the “ Company ”) announces that it has filed articles of amendment to effect the previously announced share [...]
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed
01/05/2024
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed Year-over-year Q1 revenues increase by 35% to $19.8 million Increasing 2024 revenue guidance to $83-85 million, previously $79-81 million [...]
Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
01/05/2024
Subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extensive resolution of schisis observed in two patients Provides evidence that AAV.SPR spreads laterally outside of [...]
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
01/05/2024
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) [...]
Altimmune to Participate at Two Upcoming Conferences
01/05/2024
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on [...]

Pages